Disclosures for "A Review of Economic Studies of Amyotrophic Lateral Sclerosis (ALS) in the United States")
-
Miss Gautam has nothing to disclose.
-
The institution of Dr. Hollin has received research support from MT Pharma. The institution of Dr. Hollin has received research support from Patient-Centered Outcomes Research Institute. The institution of Dr. Hollin has received research support from Shriners Children's. The institution of Dr. Hollin has received research support from Burroughs Wellcome Fund (BWF) Innovation in Regulatory Science. The institution of Dr. Hollin has received research support from National Institutes of Health.
-
Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Samus. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylym. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics.